JP3523650B2 - 新規蛋白質及びその製造方法 - Google Patents

新規蛋白質及びその製造方法

Info

Publication number
JP3523650B2
JP3523650B2 JP54374198A JP54374198A JP3523650B2 JP 3523650 B2 JP3523650 B2 JP 3523650B2 JP 54374198 A JP54374198 A JP 54374198A JP 54374198 A JP54374198 A JP 54374198A JP 3523650 B2 JP3523650 B2 JP 3523650B2
Authority
JP
Japan
Prior art keywords
protein
ocif
obm
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54374198A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO1998046644A1 (ja
Inventor
京二 山口
尚孝 保田
信明 中川
伸行 島
雅彦 木野崎
英資 津田
雅昭 後藤
和樹 矢野
昌拓 友保
文枝 小林
向洋 鷲田
高橋　　研
伴法 森永
侃二 東尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP3523650(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of JPWO1998046644A1 publication Critical patent/JPWO1998046644A1/ja
Application granted granted Critical
Publication of JP3523650B2 publication Critical patent/JP3523650B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
JP54374198A 1997-04-15 1998-04-15 新規蛋白質及びその製造方法 Expired - Lifetime JP3523650B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP9-97808 1997-04-15
JP9-151434 1997-06-09
JP15143497 1997-06-09
JP9-217897 1997-08-12
JP21789797 1997-08-12
JP22480397 1997-08-21
JP9-224803 1997-08-21
JP33224197 1997-12-02
JP9-332241 1997-12-02
PCT/JP1998/001728 WO1998046644A1 (fr) 1997-04-15 1998-04-15 Nouvelle proteine et methode de production associee

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2003169309A Division JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法

Publications (2)

Publication Number Publication Date
JPWO1998046644A1 JPWO1998046644A1 (ja) 1999-09-07
JP3523650B2 true JP3523650B2 (ja) 2004-04-26

Family

ID=27525882

Family Applications (7)

Application Number Title Priority Date Filing Date
JP54374198A Expired - Lifetime JP3523650B2 (ja) 1997-04-15 1998-04-15 新規蛋白質及びその製造方法
JP2003169309A Expired - Lifetime JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2003169309A Expired - Lifetime JP3935861B2 (ja) 1997-04-15 2003-06-13 新規蛋白質及びその製造方法
JP2004381995A Expired - Lifetime JP4230993B2 (ja) 1997-04-15 2004-12-28 新規蛋白質及びその製造方法
JP2008191860A Expired - Lifetime JP4355357B2 (ja) 1997-04-15 2008-07-25 新規蛋白質及びその製造方法
JP2008260450A Expired - Lifetime JP4878616B2 (ja) 1997-04-15 2008-10-07 新規蛋白質及びその製造方法
JP2011195938A Expired - Lifetime JP5285751B2 (ja) 1997-04-15 2011-09-08 新規蛋白質及びその製造方法
JP2013050045A Expired - Lifetime JP5593407B2 (ja) 1997-04-15 2013-03-13 新規蛋白質及びその製造方法

Country Status (21)

Country Link
US (7) US7527790B2 (enExample)
EP (3) EP1657255B1 (enExample)
JP (7) JP3523650B2 (enExample)
KR (1) KR100496063B1 (enExample)
CN (1) CN1138786C (enExample)
AT (1) ATE328006T1 (enExample)
AU (1) AU735355B2 (enExample)
CA (2) CA2257247C (enExample)
CY (1) CY2010017I2 (enExample)
DE (2) DE122010000049I1 (enExample)
DK (1) DK0911342T4 (enExample)
ES (1) ES2263204T5 (enExample)
FR (1) FR10C0048I2 (enExample)
HU (3) HU229841B1 (enExample)
IL (1) IL127115A (enExample)
LU (1) LU91759I2 (enExample)
NO (2) NO322632B1 (enExample)
NZ (1) NZ332995A (enExample)
PT (1) PT911342E (enExample)
RU (1) RU2238949C2 (enExample)
WO (1) WO1998046644A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044378A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Reagent containing fused protein of soluble rankl with epitope tag
WO2008150025A1 (ja) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
EP2389803A2 (en) 2006-10-11 2011-11-30 Oriental Yeast Co., Ltd. Methods using an osteopenia animal model
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
DE122010000046I1 (de) * 1996-12-13 2011-05-05 Schering Corp Oberflächenantigene aus Säugern
DE951551T1 (de) * 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
EP2009025B1 (en) 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
IL142557A0 (en) 1998-10-28 2002-03-10 Snow Brand Milk Products Co Ltd Remedies for bone metabolic errors
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MXPA02008144A (es) † 2000-02-23 2002-11-29 Amgen Inc Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina.
DE01973455T1 (de) 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
WO2002062990A1 (fr) * 2001-02-07 2002-08-15 Sankyo Company, Limited Anticorps et utilisation de cet anticorps
WO2002079256A1 (fr) * 2001-03-26 2002-10-10 Sankyo Company, Limited Anticorps et son utilisation
AU2002253133B2 (en) 2001-04-03 2008-02-28 Societe Des Produits Nestle S.A. Osteoprotegerin in milk
DK2270052T3 (en) 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US7462700B2 (en) * 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT2311873T (pt) 2004-01-07 2018-11-20 Novartis Vaccines & Diagnostics Inc Anticorpo monoclonal específico para m-csf e respetivos usos
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (ru) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Способ профилактики рождения больных остеопетрозом детей
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2007093050A1 (en) * 2006-02-13 2007-08-23 Olga Ornatsky Gene expression assays conducted by elemental analysis
EP2020445B1 (en) 2006-05-12 2013-01-02 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
SG10201605897RA (en) 2007-10-11 2016-09-29 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
JP2012520098A (ja) * 2009-03-30 2012-09-06 エフ．ホフマン−ラ ロシュ アーゲー ガラスの曇りを防ぐための方法
MX2011007342A (es) * 2009-04-09 2011-07-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
BR112013008255A2 (pt) 2010-10-05 2018-09-25 Daiichi Sankyo Co Ltd anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
CN104349785A (zh) * 2012-03-21 2015-02-11 达纳-法伯癌症研究所有限公司 人淋巴系器官源性抑制性基质细胞的分离和用途
NZ631509A (en) 2012-03-30 2016-09-30 Daiichi Sankyo Co Ltd Cdr-modified anti-siglec-15 antibody
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
CN105555291B (zh) 2013-08-07 2021-08-24 助育公司 用于治疗雄性不育症的抗体、化合物及其衍生物
EP3086780A4 (en) 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
BR112019004901A2 (pt) * 2016-09-13 2019-06-25 E&S Healthcare Co., Ltd. anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, seu método de preparação, molécula de ácido nucleico, vetor recombinante, célula hospedeira, kit de diagnóstico e método para fornecer informações
CN108410990B (zh) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Igfbp3在制备诊断i型神经纤维瘤合并脊柱畸形病产品中的应用
CN111205354B (zh) * 2020-01-22 2021-01-22 天津科技大学 一种提高异源蛋白分泌量的信号肽突变体及其构建方法与用途
CN111333709B (zh) * 2020-03-17 2023-09-08 吉林大学 旋毛虫肌幼虫期丝氨酸蛋白酶抑制剂的b细胞表位多肽、杂交瘤细胞株、单克隆抗体及应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
EP0192658A4 (en) 1984-07-30 1987-07-13 Salk Inst For Biological Studi RETROVIRAL GENE TRANSFER VECTORS.
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
AU651421B2 (en) * 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (ja) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2171610A1 (en) 1993-09-14 1995-03-23 Gideon A. Rodan Cdna encoding a novel human protein tyrosine phosphatase
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
DE122010000046I1 (de) * 1996-12-13 2011-05-05 Schering Corp Oberflächenantigene aus Säugern
FR2757507B1 (fr) 1996-12-20 1999-01-29 Inst Francais Du Petrole Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
AU5901598A (en) * 1996-12-20 1998-07-17 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
DE951551T1 (de) * 1996-12-23 2000-09-14 Immunex Corp., Seattle Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ES2263204T5 (es) 1997-04-15 2013-10-14 Daiichi Sankyo Company, Limited Nueva proteína y proceso para producir la misma
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
WO1998054201A1 (en) 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
EP2009025B1 (en) 1998-05-14 2011-07-27 Immunex Corporation Method of inhibiting osteoclast activity
WO2001003719A2 (en) 1999-07-09 2001-01-18 Amgen Inc. Combination therapy for conditions leading to bone loss
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DK2270052T3 (en) * 2001-06-26 2018-07-02 Amgen Inc Antibodies to OPGL
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎａｔｕｒｅ，Ｎｏｖ．１３，１９９７，Ｖｏｌ．３９０，ｐｐ．１７５−１７９

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044378A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Reagent containing fused protein of soluble rankl with epitope tag
EP2389803A2 (en) 2006-10-11 2011-11-30 Oriental Yeast Co., Ltd. Methods using an osteopenia animal model
WO2008150025A1 (ja) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
WO2010038610A1 (ja) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 新しい軟骨細胞増殖及び分化誘導剤
WO2012133914A1 (ja) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Ranklアンタゴニストを含む癌免疫増強剤

Also Published As

Publication number Publication date
HUS1400027I1 (hu) 2016-10-28
US20050208580A1 (en) 2005-09-22
US20050003457A1 (en) 2005-01-06
CA2257247C (en) 2012-09-11
DE69834699T3 (de) 2013-11-14
EP2336168A1 (en) 2011-06-22
NZ332995A (en) 2000-07-28
CA2781623A1 (en) 1998-10-22
JP2009029834A (ja) 2009-02-12
DK0911342T4 (da) 2013-07-29
US7527790B2 (en) 2009-05-05
CN1222917A (zh) 1999-07-14
ATE328006T1 (de) 2006-06-15
US7449185B2 (en) 2008-11-11
NO2010021I1 (no) 2011-01-10
DE69834699D1 (de) 2006-07-06
US20070009520A1 (en) 2007-01-11
ES2263204T3 (es) 2006-12-01
JP5593407B2 (ja) 2014-09-24
CN1138786C (zh) 2004-02-18
ES2263204T5 (es) 2013-10-14
US20080187540A9 (en) 2008-08-07
KR20040004509A (ko) 2004-01-13
US20030208045A1 (en) 2003-11-06
NO322632B1 (no) 2006-11-06
NO985848L (no) 1999-02-15
US7192718B2 (en) 2007-03-20
CA2257247A1 (en) 1998-10-22
FR10C0048I1 (enExample) 2011-01-14
AU6851898A (en) 1998-11-11
DK0911342T3 (da) 2006-08-21
DE69834699T2 (de) 2007-05-16
JP4355357B2 (ja) 2009-10-28
DE122010000049I1 (de) 2011-05-05
CY2010017I2 (el) 2012-01-25
NO985848D0 (no) 1998-12-14
US20100136011A1 (en) 2010-06-03
LU91759I2 (fr) 2011-01-24
EP0911342A1 (en) 1999-04-28
US20120329671A1 (en) 2012-12-27
JP4878616B2 (ja) 2012-02-15
HUP0000717A2 (hu) 2000-06-28
RU2238949C2 (ru) 2004-10-27
PT911342E (pt) 2006-08-31
EP0911342B2 (en) 2013-05-22
EP0911342B1 (en) 2006-05-31
JP5285751B2 (ja) 2013-09-11
JP2004041195A (ja) 2004-02-12
KR100496063B1 (ko) 2005-06-21
WO1998046644A1 (fr) 1998-10-22
JP2009013177A (ja) 2009-01-22
HU229476B1 (en) 2014-01-28
EP0911342A4 (en) 2002-11-27
US20030176647A1 (en) 2003-09-18
IL127115A0 (en) 1999-09-22
JP4230993B2 (ja) 2009-02-25
AU735355B2 (en) 2001-07-05
FR10C0048I2 (fr) 2013-08-16
NO2010021I2 (no) 2015-03-09
JP3935861B2 (ja) 2007-06-27
HU229841B1 (en) 2014-09-29
JP2012041345A (ja) 2012-03-01
HU0800628D0 (en) 2010-06-28
JP2005176847A (ja) 2005-07-07
AU735355C (en) 1998-11-11
EP1657255B1 (en) 2014-07-30
LU91759I9 (enExample) 2019-01-02
JP2013139465A (ja) 2013-07-18
CY2010017I1 (el) 2011-02-02
IL127115A (en) 2013-08-29
EP1657255A1 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
JP3523650B2 (ja) 新規蛋白質及びその製造方法
JPWO1998046644A1 (ja) 新規蛋白質及びその製造方法
AU2008200700C1 (en) Novel Protein and Process for Producing The Same
KR100436092B1 (ko) 신규단백질및그제조방법
MXPA98010700A (en) Novel protein and process for producing the same
AU2014250718A1 (en) Novel Protein and Process for Producing The Same
HK1159137A (en) Novel protein and method for producing the protein
AU2012204072A1 (en) Novel Protein and Process for Producing The Same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20031210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040209

R150 Certificate of patent or registration of utility model

Ref document number: 3523650

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080220

Year of fee payment: 4

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090220

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090220

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100220

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110220

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110220

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110220

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120220

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 9

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130220

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20240220

Year of fee payment: 20

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

EXPY Cancellation because of completion of term